Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

April 22, 2015

Provectus prioritizes pharma partners with clinical-stage PD1/PDL1s

A BioPharm Insight article reports on Provectus efforts to partner with companies having PD1 or PDL1 inhibitor agents in late-stage development, noting the recently approved joint patent with Pfizer covering the use of PV-10 in combination with systemic inhibitors of immune system regulation.

April 22, 2015

Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancer

Dermwire covers news that Provectus an Pfizer have received allowance from the FDA for a jointly held patent protecting the use of PV-10 in combination with systemic inhibitors of immune system regulation.

April 17, 2015

Audio Recording of Provectus Panel Discussion Now Available

An audio recording of Provectus' panel discussion on Thursday, April 9, 2015 at The Harvard Club of New York City is now available.

April 16, 2015

Provectus Opens Phase 3 Trial Enrollment for Investigational Melanoma Agent

Dermwire covers news that Provectus has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.

April 15, 2015

Presentation Slides Available from ChinaBio Partnering Forum 2015

Slides are now available from Provectus' presentation at ChinaBio Partnering Forum 2015.

April 13, 2015

Growth Capital Expo Presentation Slides and Webcast Available

Webcast and slides from Provectus' presentation at Growth Capital Expo 2015 are available for download.

April 13, 2015

Phase 3 trial to compare PV-10 with chemotherapy in stage III melanoma

An article appearing on Healio discusses the Phase 3 trial of PV-10 for locally advanced cutaneous melanoma that is soon to begin recruiting, and includes quotes from Dr. Sanjiv Agarwala regarding trial design.

April 10, 2015

Trials in Progress: Intralesional PV-10 vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma

A poster presentation at the HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting presents an overview of study PV-10-MM-31, Provectus' Phase 3 trial of PV-10 for locally advanced cutaneous melanoma.

April 10, 2015

Presentation Slides Available from HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting

Slides are now available from Dr. Sanjiv Agarwala's presentation at the HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting.

April 10, 2015

Slides from Provectus Panel Discussion Available

Slides from Provectus' panel discussion on Thursday, April 9, 2015 at The Harvard Club of New York City are available.

March 25, 2015

BIO Asia International Conference Presentation Slides Available

Slides from Provectus' presentation at the 12th Annual BIO Asia International Conference will be available at 2:30am EDT on March 25, 2015.

March 25, 2015

BioCentury Reports Start of Enrollment for Phase 2 PH-10 Method of Action Study

An article appearing recently in BioCentury reports that enrollment has begun for the Phase 2 trial studying PH-10's method of action.

March 25, 2015

BioCentury Reports Completion of Enrollment for PV-10 Phase 1 Method of Action Study

An article appearing recently in BioCentury reports on the completion of enrollment for the Phase 1 trial studying PV-10's method of action.

March 17, 2015

Provectus gets US patent entitled "Topical medicaments and methods for photodynamic treatment of disease"

Pharmabiz.com covers news that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 8,974,363 to Provectus. The new patent, entitled "Topical medicaments and methods for photodynamic treatment of disease," provides detailed protection of the company's investigational dermatological drug PH-10.

March 13, 2015

Provectus Biopharmaceuticals Invites You to a Panel Discussion

Provectus will host a panel discussion on Thursday, April 9, 2015 from 5:00 - 6:30 PM EDT. The discussion will take place at The Harvard Club of New York City, 35 West 44 Street in the Cambridge Room. Meeting will be posted as Provectus Biopharmaceuticals, Inc.

March 12, 2015

Webcast: Conference Call March 12 4:00 PM EDT

Provectus will hold its year-end quarterly business update conference call at 4 p.m. (EDT) to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

March 9, 2015

[Video] Presentation at European Life Science CEO Forum & Exhibition

A video of Peter Culpepper's presentation at the 8th Annual European Life Science CEO Forum & Exhibition on March 3, 2015 is now available.

March 4, 2015

PV-10 in Metastatic Melanoma: Rapid Responses Led Phase 3

An article appearing on Medscape discusses the rapid response of PV-10 seen in phase 2 melanoma testing and how this affected the phase 3 trial design.

March 4, 2015

Cityview Magazine Interviews Provectus' CEO Craig Dees, Ph.D.

Cityview Magazine recently interviewed Provectus CEO Craig Dees, Ph.D.

March 2, 2015

Presentation Slides from European Life Science CEO Forum & Exhibition

Slides from Provectus' presentation at the 8th Annual European Life Science CEO Forum & Exhibition on March 3, 2015 are now available.

more...

PRESS RELEASES

April 20, 2015

Pfizer and Provectus Biopharmaceuticals Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancer

Provectus announced today that it has received from the US Patent and Trademark Office a Notice of Allowance for a joint patent application made with Pfizer, Inc. The patent will protect use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.

April 15, 2015

Provectus Biopharmaceuticals Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma

Provectus enters phase 3 and has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma.

April 8, 2015

Provectus Biopharmaceuticals to Present at 7th Annual International Partnering Conference, ChinaBio Partnering Forum 2015, Shanghai, China

Provectus announced today that it will present at the 7th Annual International Partnering Conference, ChinaBio Partnering Forum 2015, in Shanghai, China.

April 7, 2015

Provectus Biopharmaceuticals' Data on PV-10 to Be Presented at HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting

Provectus announced today that Dr. Sanjiv Agarwala will present data on PV-10, the Company's novel investigational drug for cancer, at the HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting on Friday, April 10, 2015 at the Sheraton New York Times Square Hotel.

April 2, 2015

Provectus Biopharmaceuticals Will Present at the Growth Capital Expo, Las Vegas at 1 pm PDT on Monday April 13, 2015

Provectus announced today that it will present at the Growth Capital Expo at 1 pm PDT on Monday, April 13, 2015. The Expo is being held at Caesars Palace, April 12-14, 2015.

March 20, 2015

Provectus Biopharmaceuticals Will Present at the 12th Annual BIO Asia International Conference Wednesday, March 25, 2015

Provectus announced today that it will present at the 12th Annual BIO Asia International Conference, taking place on March 24th and 25th at the Grand Hyatt in Tokyo, Japan.

March 16, 2015

Provectus Biopharmaceuticals' Amended Protocol of PV-10 for Phase 3 Study as Treatment for Melanoma Now Available Online

Provectus announced today that the amended protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available at: http://clinicaltrials.gov/ct2/show/study/NCT02288897. The Company does not require additional review from the U.S. Food and Drug Administration(the "FDA") to start the phase 3 study, and has begun the process of gaining approval from the Institutional Review Board (IRB) of each individual site for the amended protocol.

March 12, 2015

Provectus Biopharmaceuticals Updates Market on Business Developments

Provectus today provides the market with a business update that addresses several matters.

March 12, 2015

Provectus Biopharmaceuticals Awarded PH-10 Patent by U.S. Patent and Trademark Office

Provectus announced today that it has received U.S. Patent No. 8,974,363 from the United States Patent and Trademark Office (USPTO).

March 12, 2015

Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Results

Provectus today announced its results of operations and financial condition for the fourth quarter and year ended December 31, 2014.

February 24, 2015

Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015

Provectus announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.

February 18, 2015

Provectus Biopharmaceuticals Will Present at 8th Annual European Life Science CEO Forum & Exhibition

Provectus announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.

February 10, 2015

Provectus Biopharmaceuticals Will Present at 17th Annual BIO CEO And Investor Conference Tuesday, February 10, 2015

Provectus announced today that it will present at the 17th Annual BIO CEO and Investor Conference on Tuesday, February 10,2015.

February 9, 2015

Provectus Biopharmaceuticals Met with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study

Provectus announced today that it has held a Type C meeting with the U.S. Food and Drug Administration to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.

February 6, 2015

Provectus Biopharmaceutical's PV-10 Featured in Article by Sanjiv Agarwala in Current Opinion in Oncology

Provectus announced today that an article, entitled "Intralesional therapy for advanced melanoma: promise and limitation," authored by Sanjiv S. Agarwala, MD, has been published in the March issue of Current Opinion in Oncology, now available online.

January 29, 2015

Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial Of PH-10 For Psoriasis

Provectus announced today that it has opened recruitment for its phase 2 mechanism of action trial of PH-10 for the treatment of mild to moderate psoriasis.

January 26, 2015

Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Office

Provectus announced today that it has received notification of allowance from the Chinese Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the Company's lead oncology drug candidate.

December 23, 2014

Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Markers of Psoriasis Now Available Online

Provectus announced today that the protocol for its phase 2 study of the mechanism of action of PH-10 in psoriasis is now available on ClinicalTrials.gov, Identifier NCT02322086:

December 22, 2014

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment

Provectus announced today that it will be meeting with the U.S. Food and Drug Administration (the "FDA") to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma. No date for this meeting has been agreed upon as yet.

December 17, 2014

Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin

Provectus announced today that it has agreed to sponsor the activities of the American Association of Physicians of Indian Origin (AAPI). In addition, Provectus will participate at AAPI's 2015 Global Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as well as at the Annual AAPI Conference in Orlando, Florida, running from June 17-21, 2015.

more...